Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about CGEM, unsubscribe in one click. Privacy
| PDUFA Date | Drug | Indication | Type | PoA |
|---|---|---|---|---|
| 2027-02-27 | Zipalertinib | relapsed EGFR ex20ins NSCLC | NDA | 66% |
PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area, cash runway and problems the FDA has raised with the application, as the company has disclosed them. Not investment advice. See the full PDUFA calendar →
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Anti-FLT3/CD3 Bispecific Antibody CLN-049 | Relapsed/Refractory Acute Myeloid Leukemia (AML) | Phase 1/2 · NCT05143996 | Recruiting |
| Zipalertinib (CLN-081) | Non Small Cell Lung Cancer | Phase 1/2 · NCT04036682 | Active not recruiting |
| Velinotamig specified dose on specified days. | Immune Thrombocytopenia (ITP) | Phase 1/2 · NCT07738822 | Not yet recruiting |
| EBNA-1 inhibitor VK-2019 | Nasopharyngeal Carcinoma | Phase 1/2 · NCT03682055 | Terminated |
| Carboplatin AUC 6 | Advanced Solid Tumor | Phase 1 · NCT05117476 | Active not recruiting |
| Isuventatug (CLN-619) | Multiple Myeloma | Phase 1 · NCT06381141 | Active not recruiting |
| Anti-CD19/CD3 T-cell Engaging Bispecific… | Sjögren | Phase 1 · NCT07041099 | Recruiting |
| Datopotamab Deruxtecan | Advanced Solid Tumor | Phase 1 · NCT05117476 | Active not recruiting |
Also used in these trials (approved or third-party drugs, not CGEM's own candidates): Azacitidine, IL-2/IL-12-based Fusion Protein CLN-617, Paclitaxel, Pembrolizumab, Pemetrexed Disodium, Venetoclax.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
CGEM holds $311.5M in cash and short-term investments (as of Sep 30, 2026) and burns about $40.7M/quarter from operations, an estimated runway of 23 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 41 · Elevated
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CGEM files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Lynx1 Capital Management LP 10% owner |
Insider | 8,963,500 | 13.81% | 2025-10-28 |
| BVF PARTNERS L P/IL | Institution (13G, 5%+) | 6,491,123 | 10.00% | 2026-06-30 |
| T. Rowe Price Associates, Inc. | Institution (13G, 5%+) | 3,825,950 | 5.89% | 2026-06-30 |
| Kynam Capital Management, LP | Institution (13G, 5%+) | 3,114,132 | 4.80% | 2025-12-31 |
| Nadim Ahmed President and CEO, Director · +828,000 options |
Insider | 390,803 | 0.60% | 2026-02-24 |
| Jeffrey Alan Jones Chief Medical Officer · +300,000 options |
Insider | 159,968 | 0.25% | 2026-02-24 |
| Jennifer Michaelson Chief Scientific Officer · +190,182 options |
Insider | 158,649 | 0.24% | 2026-11-05 |
| Jacquelyn L Sumer Chief Legal Officer · +230,000 options |
Insider | 130,559 | 0.20% | 2026-06-30 |
| Mary Kay Fenton Chief Financial Officer · +137,500 options |
Insider | 127,921 | 0.20% | 2026-06-30 |
Share count 64,920,924 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CGEM and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →